Interleukin-1 family

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

Retrieved on: 
Tuesday, August 8, 2023
NRS, ACR, APG system, RA, Arthritis, Interleukin-1 family, Enterprise master patient index, Arthritis Foundation, Quality of life, American College of Rheumatology, Tenderness, Inflammation, Person, Rheumatoid arthritis, CDC, Pain, Joint, American College, Phase, CDAI, MTX, Safety, Pharmaceutical industry

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.

Key Points: 
  • AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.
  • Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).
  • The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks.
  • In addition, it is expected that 300,000 children will suffer from juvenile arthritis (Arthritis Foundation, 2023).

Innovative Spinal Biomaterial Demonstrates Early Healing in Retrospective Study

Retrieved on: 
Thursday, September 8, 2022
Elasticity, Osteoporosis, University, PEEK, CEO, Immunomodulation, McGowan, Research, Scoliosis, Sheep, Cohort study, Engineering, Doctor of Philosophy, Smoker, Subsidence, CT, Pathology, Inflammation, Foreign Bodies, Diabetes, Science, Osseointegration, Spine, McGowan Institute for Regenerative Medicine, Rabbit, Interleukin 12, GLOBE, Neuroscience, Center, Interleukin 6, Yale University, Interleukin-1 family, Immune system, Regenerative medicine, Johns, Titanium, Interleukin 10, Founder, LLC, Risk, Industry, Osteopenia, Patient, High-performance plastics, Silk, Medical imaging, DVM, MD

that validates ZFUZE as the first homogenous new biomaterial introduced in more than 20 years.

Key Points: 
  • that validates ZFUZE as the first homogenous new biomaterial introduced in more than 20 years.
  • The ZFUZE retrospective study was conducted by Paul Kraemer, MD, at the Indiana Spine Group and consisted of 41 patients who underwent TLIF [define] single and double level lumbar interbody fusions.
  • "Maybe the most important thing about the study was there were no exclusion criteria," Dr. Kraemer said.
  • Medical Metrics LLC performed third-party radiographic fusion analysis via CT scan for 91.4% fusion rates at an early 8-month timepoint.

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Retrieved on: 
Wednesday, January 26, 2022
Risk, Pharmacokinetics, Forward-looking statement, Arthritis, SEC, Inflammation, NASDAQ, Rheumatology, Industry, Disease, Syringe, Interleukin-1 family, Patient, Infection, GLOBE, APG system, Pain, Safety, Terminology, Pharmaceutical industry

The Phase I study represents the launch of the clinical program for Natrunix-SQ for the treatment of rheumatological diseases.

Key Points: 
  • The Phase I study represents the launch of the clinical program for Natrunix-SQ for the treatment of rheumatological diseases.
  • Upon successful completion of the Phase I study, multiple Phase II studies to evaluate Natrunix-SQ in rheumatology are planned.
  • The unique approach of Natrunix-SQ to blocking interleukin-1-driven inflammation holds promise as a new generation of anti-inflammatory therapy in arthritis.
  • XBiotech has the manufacturing capability to produce drug product used for the clinical programs and for commercialization of the candidate therapy for arthritis.

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research

Retrieved on: 
Saturday, November 27, 2021
World Health Organization, National academy, Emergency Use Authorization, Death, Juvenile idiopathic arthritis, Federation of European Pharmacological Societies, Cardiac myxoma, Signal transduction, Rheumatology, History, Risk, Nobel Prize, Castleman, World, Drug development, Lists of diseases, Food, IL-1, Interleukin-1 family, Degenerative disease, Lecture, Cancer, Mouth, Ventilation, Tocilizumab, Research, Castleman disease, TNF, News, National, Conference, Physiology, Medical school, TNFR1, Clinical trial, Human, COVID-19, Cytokine, Taipei Medical University, Interleukin 6, DRS, APFP, Tang Prize, Type 2 diabetes, Patient, Systemic, IL-1R, US Food Sovereignty Alliance, Inflammation, Translation, JIA, Novartis, Rheumatoid arthritis, IL-6, RNA, Canakinumab, Fibrosis, Pharmaceutical industry

Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.

Key Points: 
  • Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.
  • It was a journey that took them from basic research to drug development and clinical application.
  • These three lectures by the 2020 Tang Prize laureates in Biopharmaceutical Science will be premiered on the Tang Prize YouTube channel from 4 p.m. to 7 p.m. (GMT+8) on November 27.
  • To watch the complete version of the "2020 Tang Prize Laureate's Lectures for Biopharmaceutical Science," please consult the schedule below.

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research

Retrieved on: 
Saturday, November 27, 2021
Lecture, Systemic, Taipei Medical University, National, Degenerative disease, National academy, Conference, Translation, Medical school, Federation of European Pharmacological Societies, Rheumatoid arthritis, TNFR1, IL-6, Inflammation, COVID-19, Cytokine, Research, Nobel Prize, Interleukin 6, Science, DRS, APFP, TNF, Interleukin-1 family, Pharmaceutical industry

Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.

Key Points: 
  • Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.
  • In 1977, the research outcomes were published in the Proceedings of the National Academy of Sciences.
  • He also shed light on IL-6's effects on autoimmune diseases and how IL-6 can trigger cytokine storms.
  • To help the public gain a better understanding of the latest progress made in biomedical sciences, the Tang Prize Foundation will make these three lectures available on its official website ( https://www.tang-prize.org ) afterwards.

2020 Tang Prize Awarding Ceremony and Laureate Lecture Go Virtual on November 20 and 27, 2021

Retrieved on: 
Friday, November 5, 2021
Facebook Messenger, Rule of law, Interleukin 6, Leibniz Center for Law, Cytokine, Center, Systemic, Knowledge, Tang Prize, Society, COVID-19, PIL, Research, Inflammation, Lecture, Bangladesh Environmental Lawyers Association, Interleukin-1 family, YouTube, Foundation, Association, Social, Social justice, Degenerative disease, Sustainable development, Public interest litigation in India, Translation, Justice

TAIPEI, Nov. 4, 2021 /PRNewswire/ -- The 2020 Tang Prize Awarding Ceremony is scheduled to be held online at 2p.m.

Key Points: 
  • TAIPEI, Nov. 4, 2021 /PRNewswire/ -- The 2020 Tang Prize Awarding Ceremony is scheduled to be held online at 2p.m.
  • The Tang Prize Foundation will livestream the whole event, which features eight laureates receiving the awards and making their acceptance speeches.
  • In conjunction with the forthcoming 4th Tang Prize Awarding Ceremony, eight laureate's lectures have been scheduled for November 20 and 27.
  • We welcome everyone to go to the Tang Prize's official YouTube channel ( https://www.youtube.com/user/theTangPrize ) or Facebook Page ( https://www.facebook.com/tangprize/ ) to watch the awarding ceremony and laureate lectures.

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Arthritis, Autoimmune diseases, Rheumatology, Ankylosing spondylitis, Axial spondyloarthritis, G protein-coupled receptors, Spondyloarthropathy, Interleukin-1 family, Prostaglandin E

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT.
  • The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Clinical medicine, Cytokines, Branches of biology, Interleukins, Occupational diseases, Interleukin 1 receptor antagonist, Interleukin-1 family, Obliterative bronchiolitis, Lung transplantation, Bronchiolitis

Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.

Key Points: 
  • Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.
  • Further, treatment via a handheld nebulizer may provide a convenient portable intervention option for lung transplant patients experiencing BOS.
  • ALTA-2530, a recombinant human IL-1Ra, binds competitively to the IL-1 receptor to attenuate the inflammatory response.
  • ALTA-2530 is a recombinant human interleukin-1 receptor antagonist under development for bronchiolitis obliterans syndrome (BOS), a life-threatening form of chronic lung allograft dysfunction (CLAD) that frequently presents following lung transplantation.

FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Immunosuppressants, Anakinra, Cytokines, Kinneret, Interleukin 1 receptor antagonist, Interleukins, Arthritis, Interleukin-1 family

The safety and efficacy of KINERET were evaluated in a long-term natural history study, including nine patients with DIRA (ages 1 month to 9 years at start of KINERET treatment) treated with KINERET for up to 10 years.

Key Points: 
  • The safety and efficacy of KINERET were evaluated in a long-term natural history study, including nine patients with DIRA (ages 1 month to 9 years at start of KINERET treatment) treated with KINERET for up to 10 years.
  • At the last visit during the first KINERET treatment period, the dose ranged from 2.2 and 6.1 mg/kg/day.
  • KINERET(anakinra) is a prescription medicine called an interleukin-1 receptor antagonist (IL-1Ra) used to:
    KINERET is not for children with Juvenile Rheumatoid Arthritis.
  • A complete list of any of the ingredients in KINERET can be found at the end of the patient leaflet.